2/25
06:24 am
nbix
Neurocrine Biosciences (NBIX) was upgraded by Wolfe Research to "strong-buy".
Low
Report
Neurocrine Biosciences (NBIX) was upgraded by Wolfe Research to "strong-buy".
2/24
04:29 pm
nbix
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March [Yahoo! Finance]
Low
Report
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March [Yahoo! Finance]
2/24
04:01 pm
nbix
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
Low
Report
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
2/24
08:00 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $160.00 price target on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $160.00 price target on the stock.
2/19
07:26 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
2/18
09:49 pm
nbix
Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza [Yahoo! Finance]
Low
Report
Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza [Yahoo! Finance]
2/17
02:48 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at JPMorgan Chase & Co. from $177.00 to $176.00. They now have an "overweight" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at JPMorgan Chase & Co. from $177.00 to $176.00. They now have an "overweight" rating on the stock.
2/17
11:53 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Truist Financial Corporation from $169.00 to $140.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Truist Financial Corporation from $169.00 to $140.00. They now have a "buy" rating on the stock.
2/16
01:08 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by analysts at
Wall
Medium
Report
Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by analysts at
Wall
2/14
06:51 am
nbix
A Look At Neurocrine Biosciences (NBIX) Valuation After Strong 2025 Results And 2026 Guidance [Yahoo! Finance]
Medium
Report
A Look At Neurocrine Biosciences (NBIX) Valuation After Strong 2025 Results And 2026 Guidance [Yahoo! Finance]
2/13
09:47 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Wells Fargo & Company from $180.00 to $175.00. They now have an "overweight" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Wells Fargo & Company from $180.00 to $175.00. They now have an "overweight" rating on the stock.
2/13
04:22 am
nbix
Neurocrine Biosciences: Growth Beyond Just Ingrezza [Seeking Alpha]
Low
Report
Neurocrine Biosciences: Growth Beyond Just Ingrezza [Seeking Alpha]
2/12
02:52 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Citigroup Inc. from $203.00 to $204.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Citigroup Inc. from $203.00 to $204.00. They now have a "buy" rating on the stock.
2/12
02:21 pm
nbix
Neurocrine Biosciences: Expanding Opportunities, 2026 Will Be Less Exciting [Seeking Alpha]
Low
Report
Neurocrine Biosciences: Expanding Opportunities, 2026 Will Be Less Exciting [Seeking Alpha]
2/12
12:52 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Royal Bank Of Canada from $180.00 to $177.00. They now have an "outperform" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Royal Bank Of Canada from $180.00 to $177.00. They now have an "outperform" rating on the stock.
2/12
12:26 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at BMO Capital Markets from $147.00 to $140.00. They now have a "market perform" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at BMO Capital Markets from $147.00 to $140.00. They now have a "market perform" rating on the stock.
2/12
11:14 am
nbix
Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says [Yahoo! Finance]
Low
Report
Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says [Yahoo! Finance]
2/12
09:46 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Wedbush from $149.00 to $151.00. They now have an "outperform" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Wedbush from $149.00 to $151.00. They now have an "outperform" rating on the stock.
2/12
08:04 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Needham & Company LLC from $187.00 to $185.00. They now have a "buy" rating on the stock.
High
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Needham & Company LLC from $187.00 to $185.00. They now have a "buy" rating on the stock.
2/12
08:04 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at HC Wainwright from $198.00 to $192.00. They now have a "buy" rating on the stock.
High
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at HC Wainwright from $198.00 to $192.00. They now have a "buy" rating on the stock.
2/11
07:02 pm
nbix
Neurocrine Biosciences Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Neurocrine Biosciences Q4 Earnings Call Highlights [Yahoo! Finance]
2/11
04:01 pm
nbix
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
High
Report
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
2/8
02:04 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) was upgraded by analysts at
Wall St
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) was upgraded by analysts at
Wall St
2/7
10:22 am
nbix
The Bull Case For Neurocrine Biosciences (NBIX) Could Change Following Its Next-Gen VMAT2 Phase 2 Trial [Yahoo! Finance]
Low
Report
The Bull Case For Neurocrine Biosciences (NBIX) Could Change Following Its Next-Gen VMAT2 Phase 2 Trial [Yahoo! Finance]
1/26
08:42 am
nbix
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia [Yahoo! Finance]
Medium
Report
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia [Yahoo! Finance]